# CJC-1295 FAQ: Safety, Side Effects, FDA Status, and the Record

> CJC-1295 FAQ: is it FDA approved, is it safe, what are the side effects, does it affect testosterone — answered from the published record and cited where quantitative.

Direct answers from the published CJC-1295 record — safety, side effects, regulatory status, and the limits of the data.

## What does CJC-1295 do?

It is a long-acting GHRH analog that binds the pituitary GHRH receptor to stimulate growth-hormone release and, downstream, raise IGF-1; in healthy adults single doses elevated GH and IGF-1 for days [1]. Its defining feature is duration: a single dose acts like a slow, sustained GHRH signal, with a half-life of 5.8 to 8.1 days [1].

## What is CJC-1295?

A synthetic GHRH analog built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds covalent serum-albumin conjugation for a multi-day half-life, while the no-DAC form (Modified GRF 1-29) is short-acting [2]. It exists in two pharmacokinetically distinct forms under one name, which is the root of most confusion about it.

## Is CJC-1295 safe?

It is an unapproved research chemical with no large human safety trials; sustained GH/IGF-1 elevation raises theoretical concerns including fluid retention, the epidemiologic link between higher IGF-1 and some cancers, and immunogenicity. The published evidence base in healthy adults is thin and short-term, limited to early PK studies [1][3].

## Are CJC-1295 peptides safe?

Safety is not established in large human trials. Reported and theoretical concerns include fluid retention and edema from GH-axis stimulation, IGF-1/cancer-risk epidemiology, and FDA-cited immunogenicity; CJC-1295 remains an unapproved research chemical, and no long-term safety study in healthy adults exists [1].

## What are the side effects of CJC-1295?

Documented and theoretical concerns center on GH-axis effects: fluid retention and edema from GH-driven sodium retention, effects on insulin sensitivity, and epidemiologic links between higher IGF-1 and some cancers. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee also flagged immunogenicity. These are mechanism-based and population-level concerns, not a catalogued adverse-event profile from large trials [1].

## Is CJC-1295 FDA approved?

No. CJC-1295 is not approved by the FDA or any major regulator for human use; it is handled as a research chemical and was reviewed but not recommended for the 503A compounding bulks list at the 2024 FDA Pharmacy Compounding Advisory Committee. FDA briefing materials cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295.

## Is CJC-1295 a steroid?

No. It is a peptide GHRH analog that works upstream on the GH/IGF-1 axis, not a steroid hormone; it stimulates the body's own pituitary GH secretion rather than supplying an exogenous steroid [1][2]. Its mechanism is receptor signaling at the pituitary, not steroid-receptor binding.

## Does CJC affect testosterone?

CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis; the published CJC-1295 literature does not establish a direct testosterone effect, and claims that it raises or lowers testosterone are not supported by controlled human data [1]. The hormone it moves is GH, and downstream IGF-1 — not testosterone.

## Does CJC-1295 lower testosterone?

There is no controlled human evidence that CJC-1295 lowers testosterone; it operates on the GH/IGF-1 axis rather than the hypothalamic-pituitary-gonadal axis, so testosterone effects are not part of its documented profile [1]. Any claim of a testosterone-lowering effect is unsupported by the published record.

## Are peptides safer than TRT?

There is no head-to-head evidence ranking GH-axis peptides like CJC-1295 against testosterone-replacement therapy on safety; CJC-1295 is unapproved with limited human data and acts on a different axis, so a safety comparison is not supported by controlled trials [1]. The two address different hormone systems, and no study compares them directly.

## What does the published human research on CJC-1295 actually show?

Limited early-phase PK work: dose-dependent multi-day GH/IGF-1 elevation with a 5.8-8.1 day half-life [1], preserved GH pulsatility [3], and serum-proteome shifts correlating with IGF-1 [4]. No large efficacy or long-term safety trials exist, and the entire human record is a handful of small studies in healthy volunteers.

## How does CJC-1295 affect IGF-1 levels?

In healthy men a single 60-90 micrograms per kilogram dose raised basal GH about 7.5-fold and mean GH about 46% and IGF-1 about 45% one week later [3], consistent with the sustained multi-day kinetics of the DAC form [1]. It raises IGF-1 indirectly, by first raising the GH that drives hepatic IGF-1 production.

## What is CJC-1295 with DAC?

The Drug Affinity Complex variant carries a maleimidopropionyl-lysine handle that covalently binds the Cys34 thiol of serum albumin, forming a roughly 66 kDa peptide-albumin conjugate detectable in plasma beyond 72 hours [2]. That albumin tether is what gives the DAC form its multi-day duration, and the [CJC-1295 DAC](/cjc-1295-dac) page covers it in full.

## What is CJC-1295 DAC?

CJC-1295 DAC is the albumin-conjugated, long-acting form (half-life 5.8-8.1 days); it is distinct from no-DAC "Modified GRF 1-29," which keeps the four substitutions but lacks the albumin-binding moiety and is short-acting [1][2]. The two are pharmacokinetically opposite despite sharing a name and a backbone.

## How much CJC-1295 should I take?

There is no established human dose; CJC-1295 is not approved for human use. Published research used single subcutaneous 30-90 micrograms per kilogram doses in PK studies [1]; circulating "protocols" are not derived from controlled human trials. This digest reports research doses as context, not as guidance — see the [dosing context in studies](/dosage).

## How much CJC-1295 DAC should I take?

No validated human dose exists for the DAC form. Human PK studies used single 30, 60, or 90 micrograms per kilogram subcutaneous doses; the multi-day half-life (5.8-8.1 days) means it accumulates differently from short-acting no-DAC [1]. Reported as research context only, not a regimen for an unapproved compound.

## How much CJC-1295 / ipamorelin should I take?

No controlled human trial establishes a CJC-1295/ipamorelin dose. The pairing rests on a two-receptor (GHRH + GHRP) synergy rationale, but circulating fixed-dose protocols are not derived from clinical trials [5]. The mechanism supports combining the pathways; it does not supply a validated dose, and this site provides none.

## How to reconstitute CJC-1295?

It ships lyophilized and is reconstituted with bacteriostatic water and refrigerated in research handling; oral bioavailability is negligible, so subcutaneous injection is the route studied [1]. This describes laboratory handling of a research chemical, not human-use instructions, and is covered alongside the [dosing context in studies](/dosage).

## Where to inject CJC-1295?

Published studies used subcutaneous injection (with intravenous in early GRF(1-29) PK work) [1][2]; this reflects the route studied in the literature and is not a use recommendation for an unapproved compound. As a peptide with negligible oral bioavailability, injection is the only route the research employed [1].

## What is CJC-1295 ipamorelin?

It is the common research pairing of CJC-1295 (a GHRH analog) with ipamorelin (a selective GH secretagogue acting on the ghrelin/GHS receptor); the two-pathway combination is studied because the receptors are distinct and their GH-release effects can be supra-additive [5]. It is a research pairing, not an approved combination product.

## Does CJC-1295 and ipamorelin work?

The rationale is mechanistic: GHRH analogs and GHRPs act through distinct receptors and synergize, and ghrelin/secretagogues potentiate GHRH-induced GH release [5]. Direct controlled-trial efficacy data for the specific pairing in healthy adults are lacking, so the synergy is inferred from pharmacology rather than demonstrated in an endpoint trial.

## What does the research describe CJC-1295 doing?

In study settings the measurable changes were biochemical: sustained multi-day rises in GH and IGF-1 with preserved GH pulsatility [1][3], a 4-fold GH-AUC increase over unconjugated peptide in rats [2], and normalized growth in GHRH-knockout mice [7]. This describes research observations, not promised outcomes in any individual, and effects on body composition in healthy people are not established.

## What to expect when taking CJC-1295?

In study settings, the measurable changes were biochemical: sustained multi-day rises in GH and IGF-1 with preserved GH pulsatility [1][3]. This describes research observations, not promised outcomes in any individual. CJC-1295 is unapproved, the human record is a handful of small PK studies, and nothing here should be read as a description of what an individual will experience.

---

A curated night-board of the CJC-1295 record — each study, kinetic figure, and honest gap lit in its own tile and weighed by what the literature can actually carry, with no clinic behind the board and nothing here dispensed or sold.